ClinicalTrials.gg
Drug

Ubrogepant clinical trials

Also written UBRELVY and MK-1602.

studies test it
15
open now
2
in phase 3
7
first study started
2012

How each study uses ubrogepant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ubrogepant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
23 Dec 2019 · UBRELVY · NDA 211765 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ubrogepant
11

Brand

UBRELVY
5

Development codes

MK-1602
2

Studies by the year they started

15 studies that test it; most in 2022 (5)

Studies that test ubrogepant, by start year
YearStudies
20122
20163
20191
20201
20211
20225
20241
20261

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
2
Phase 3
7
Phase 4
2
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 13 · Other 2

AbbVie (7) · Allergan (6) · Chicago Headache Center & Research Institute (1) · Universitaire Ziekenhuizen KU Leuven (1)

Often tested with

Tested in the same studies.

Atogepant (2) · Sumatriptan (1) · Erenumab (1) · Galcanezumab (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2, 2 in phase 3

Studies that test ubrogepant, phase 3 first.

Studies

Open first, then newest update. How each study uses ubrogepant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 15

Given beside what is tested · 1 — ubrogepant is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with ubrogepant

Codes

What other systems call ubrogepant · ClinicalTrials.gg INT000647

  • MeSH (NLM) C000615620ubrogepantConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) AD0O8X2QJRUBROGEPANTConfirmed FDA, NLM, Wikidata
  • RxNorm 2268216One source FDA
  • Wikidata Q27273878ubrogepantConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C152790UbrogepantOne source FDA
  • DrugBank DB15328One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.